Literature DB >> 17043121

Comparative bactericidal activities of daptomycin and vancomycin against glycopeptide-intermediate Staphylococcus aureus (GISA) and heterogeneous GISA isolates.

Mandy Wootton1, Alasdair P MacGowan, Timothy R Walsh.   

Abstract

Staphylococcus aureus strains from the U.S. SENTRY Antimicrobial Surveillance Program, 2002-2003, glycopeptide-intermediate S. aureus (GISA) strains, and heterogeneous GISA (hGISA) strains were used to compare bactericidal activities of daptomycin and vancomycin using MICs and minimum bactericidal concentrations. Glycopeptide-susceptible S. aureus and hGISA strains were further studied by using time-kill curves. For all isolates, the daptomycin MIC50 and MIC90 are four times lower and the log drops in viable counts at 6 h and 24 h are significantly greater than those for vancomycin.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17043121      PMCID: PMC1693982          DOI: 10.1128/AAC.00678-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Resistance studies with daptomycin.

Authors:  J A Silverman; N Oliver; T Andrew; T Li
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004.

Authors: 
Journal:  Am J Infect Control       Date:  2004-12       Impact factor: 2.918

3.  Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin.

Authors:  K Hiramatsu; N Aritaka; H Hanaki; S Kawasaki; Y Hosoda; S Hori; Y Fukuchi; I Kobayashi
Journal:  Lancet       Date:  1997-12-06       Impact factor: 79.321

4.  Daptomycin: a novel agent for Gram-positive infections.

Authors:  F P Tally; M Zeckel; M M Wasilewski; C Carini; C L Berman; G L Drusano; F B Oleson
Journal:  Expert Opin Investig Drugs       Date:  1999-08       Impact factor: 6.206

5.  Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin.

Authors:  George Sakoulas; Jeff Alder; Claudie Thauvin-Eliopoulos; Robert C Moellering; George M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

6.  A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital.

Authors:  M Wootton; R A Howe; R Hillman; T R Walsh; P M Bennett; A P MacGowan
Journal:  J Antimicrob Chemother       Date:  2001-04       Impact factor: 5.790

7.  The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges.

Authors:  Sara E Cosgrove; Youlin Qi; Keith S Kaye; Stephan Harbarth; Adolf W Karchmer; Yehuda Carmeli
Journal:  Infect Control Hosp Epidemiol       Date:  2005-02       Impact factor: 3.254

Review 8.  The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus.

Authors:  Timothy R Walsh; Robin A Howe
Journal:  Annu Rev Microbiol       Date:  2002-01-30       Impact factor: 15.500

9.  Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus.

Authors:  Longzhu Cui; Eiji Tominaga; Hui-Min Neoh; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

Review 10.  Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens.

Authors:  Christopher F Carpenter; Henry F Chambers
Journal:  Clin Infect Dis       Date:  2004-03-11       Impact factor: 9.079

View more
  26 in total

1.  Inhibitory and bactericidal activities of daptomycin, vancomycin, and teicoplanin against methicillin-resistant Staphylococcus aureus isolates collected from 1985 to 2007.

Authors:  Maria M Traczewski; Bradley D Katz; Judith N Steenbergen; Steven D Brown
Journal:  Antimicrob Agents Chemother       Date:  2009-02-17       Impact factor: 5.191

2.  Incidence and characteristics of vancomycin nonsusceptible strains of methicillin-resistant Staphylococcus aureus at Hershey Medical Center.

Authors:  Klaudia Kosowska-Shick; Lois M Ednie; Pamela McGhee; Kathy Smith; Cynthia D Todd; Amanda Wehler; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2008-10-06       Impact factor: 5.191

3.  Precision of vancomycin and daptomycin MICs for methicillin-resistant Staphylococcus aureus and effect of subculture and storage.

Authors:  Carmen L Charlton; Janet A Hindler; John Turnidge; Romney M Humphries
Journal:  J Clin Microbiol       Date:  2014-08-20       Impact factor: 5.948

4.  Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect").

Authors:  Soo-Jin Yang; Yan Q Xiong; Susan Boyle-Vavra; Robert Daum; Tiffanny Jones; Arnold S Bayer
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

Review 5.  Population biology of Gram-positive pathogens: high-risk clones for dissemination of antibiotic resistance.

Authors:  Rob J L Willems; William P Hanage; Debra E Bessen; Edward J Feil
Journal:  FEMS Microbiol Rev       Date:  2011-07-04       Impact factor: 16.408

6.  daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.

Authors:  Warren E Rose; Steven N Leonard; George Sakoulas; Glenn W Kaatz; Marcus J Zervos; Anjly Sheth; Christopher F Carpenter; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2007-11-12       Impact factor: 5.191

7.  Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding.

Authors:  Tiffanny Jones; Michael R Yeaman; George Sakoulas; Soo-Jin Yang; Richard A Proctor; Hans-Georg Sahl; Jacques Schrenzel; Yan Q Xiong; Arnold S Bayer
Journal:  Antimicrob Agents Chemother       Date:  2007-10-22       Impact factor: 5.191

8.  Outcomes with daptomycin in the treatment of Staphylococcus aureus infections with a range of vancomycin MICs.

Authors:  Jason A Crompton; Donald S North; MinJung Yoon; Judith N Steenbergen; Kenneth C Lamp; Graeme N Forrest
Journal:  J Antimicrob Chemother       Date:  2010-06-16       Impact factor: 5.790

9.  The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas.

Authors:  P E Pertel; B I Eisenstein; A S Link; B Donfrid; E J A Biermann; P Bernardo; W J Martone
Journal:  Int J Clin Pract       Date:  2009-03       Impact factor: 2.503

Review 10.  Daptomycin in bone and joint infections: a review of the literature.

Authors:  Dennis A K Rice; Luke Mendez-Vigo
Journal:  Arch Orthop Trauma Surg       Date:  2008-11-07       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.